Migraine and calcitonin-gene related peptide

Ken Sharlin

January 28, 2020
JTMultimidia/Pexels
The U.S. Food and Drug Administration recently approved the fourth new drug to treat migraine since May 2018. It has been nearly a decade since the approval of any new migraine medicines, and for those patients in the conventional care system, these new treatments are a welcome sigh of relief. What makes each of these medications unique is that they all target calcitonin gene-related peptide (CGRP). But what about patients who are seeking a more natural solution to their migraines? By the time…
gold-icon-ko.png.medium.800x800.pngBecome a Gold Member to Access this Content
About the Author:

Ken Sharlin

Ken Sharlin

Ken Sharlin is a board-certified neurologist, consultant, functional medicine practitioner, Assistant Clinical Professor, researcher, author, and speaker. His medical degrees are from Emory University, The University of Virginia, and Vanderbilt University. His functional medicine certification is through The Institute for Functional Medicine.

He is author of the #1 best-seller The Healthy Brain Toolbox: Neurologist-Proven Strategies to Improve Memory Loss and Protect Your Aging Brain. His most recent publication, Reversal of Cognitive Decline: 100 Patients, can be found in the peer-reviewed Journal of Alzheimer’s & Parkinsonism, and he has been the primary investigator in several pharma-sponsored clinical trials that have helped bring new therapeutics to market.

Dr. Sharlin practices general neurology, and directs his functional medicine program, Brain Tune Up!, in Ozark, Missouri.

© 2024 Diversified Communications. All rights reserved.
Diversified Communications